Will Galafold Be Able to Aid FOLD's Top Line Heading Into Q4 Earnings? [Yahoo! Finance]
BioMarin Pharmaceutical Inc. (BMRN)
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.biomarin.com
Company Research
Source: Yahoo! Finance
Galafold is approved for treating Fabry disease in patients who have amenable genetic variants. The drug is approved in several countries across the world, including the United States, the European Union, the United Kingdom and Japan. Galafold has been a key top-line driver for the company in recent quarters. In the first nine months of 2025, Galafold generated sales worth $371.5 million, which increased around 12% on a year-over-year basis. The drug contributed more than 80% of Amicus' net product sales during the same time. As Amicus is gearing up to report its fourth-quarter results, investors will be closely watching the sales performance of Galafold. Galafold sales are likely to have been driven by strong commercial execution in all markets as well as strong compliance. The drug also has a strong IP portfolio in the United States, providing patent protection through 2038. Meanwhile, the recent settlement of the Galafold patent litigation with Teva Pharmaceuticals TEVA mark
Show less
Read more
Impact Snapshot
Event Time:
BMRN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMRN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMRN alerts
High impacting BioMarin Pharmaceutical Inc. news events
Weekly update
A roundup of the hottest topics
BMRN
News
- Making U.S. biotech more competitive with China's could help rare disease patients, experts say [CNBC]CNBC
- Does BioMarin Pharmaceutical (BMRN) Price Weakness Contrast With Its Cash Flow Valuation? [Yahoo! Finance]Yahoo! Finance
- BMRN or TARS: Which Is the Better Value Stock Right Now? [Yahoo! Finance]Yahoo! Finance
- BioMarin Pharmaceutical touts $3.2B 2025 revenue, Voxzogo surge and Amicus deal at JPM Conference [Yahoo! Finance]Yahoo! Finance
- BioMarin Appoints Arpit Davé Chief Digital and Information Officer [Yahoo! Finance]Yahoo! Finance
BMRN
Earnings
- 10/27/25 - Miss
BMRN
Sec Filings
- 1/12/26 - Form 8-K
- 12/22/25 - Form 8-K
- 12/19/25 - Form 8-K
- BMRN's page on the SEC website